Canadian journal of ophthalmology. Journal canadien d'ophtalmologie最新文献

{"title":"Conjunctival rhabdomyosarcoma presenting as a diagnostic challenge in a young girl.","authors":"Matthew E Wei, Rolika Bansal, Tatyana Milman, Carol L Shields","doi":"10.1016/j.jcjo.2026.06.016","DOIUrl":"10.1016/j.jcjo.2026.06.016","url":null,"abstract":"","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148444401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial board: color pantone 5405c+black","authors":"","doi":"10.1016/S0008-4182(26)00265-6","DOIUrl":"10.1016/S0008-4182(26)00265-6","url":null,"abstract":"","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"61 4","pages":"Page A2"},"PeriodicalIF":2.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148770356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A severe case of panitumumab-associated cicatricial ectropion and periorbital dermatitis","authors":"Andrew Samuel, Abbie Lai, Daniela AbouAssali, Victor Penner","doi":"10.1016/j.jcjo.2026.03.008","DOIUrl":"10.1016/j.jcjo.2026.03.008","url":null,"abstract":"","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"61 4","pages":"Pages 1039-1041"},"PeriodicalIF":2.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147580700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for pentosan polysulfate maculopathy","authors":"Sakshi Shiromani,&nbsp;Afif Martini,&nbsp;Xiaxian Ou,&nbsp;Brian P. Hall,&nbsp;Christian A. Leal,&nbsp;Kenneth J. Rosengren,&nbsp;Xiangqin Cui,&nbsp;Nieraj Jain","doi":"10.1016/j.jcjo.2026.03.011","DOIUrl":"10.1016/j.jcjo.2026.03.011","url":null,"abstract":"<div><h3>Objective</h3><div>To identify risk factors for pentosan polysulfate (PPS) maculopathy.</div></div><div><h3>Methods</h3><div>Cross-sectional study of PPS-exposed individuals seen at Emory Eye Center from January 2018 to March 2024. Data from standardized questionnaires and fundus imaging were evaluated. Multivariate analyses were used to evaluate toxicity risk factors, and subgroup analysis was used to compare characteristics in low-exposure (&lt;800 g) and high-exposure (&gt;1500 g) groups.</div></div><div><h3>Results</h3><div>In total, 187 patients (mean age 59.5±13.8 years, 84.5% female) underwent screening. Risk of toxicity was dose-dependent, with those in the greatest exposure quartile (≥2000 g) showing the greatest risk (odds ratio [OR] 39.8, 95% confidence interval [CI] 10.6–205.1, <em>P</em> &lt; .001). Other factors associated with risk included cumulative dose per body weight (OR 1.1, 95% CI 1.0–1.1, <em>P</em> &lt; .001), female sex (OR 8.1, 95% CI 1.2–75.9, <em>P</em> = .04), older age (OR 1.03, 95% CI 1.02–1.1, <em>P</em> = .046), and inflammatory bowel disease or irritable bowel syndrome (OR 2.8, 95% CI 1.2–6.6, <em>P</em> = .02). In low-exposure cases (&lt;800 g), those with maculopathy were older (67.1 vs 56.9 years, <em>P</em> = .01), had longer PPS exposure (11 vs 7.9 years, <em>P</em> = .03), a greater dose per body weight (9.7 vs 5.1 g/kg, <em>P</em> &lt; .001), and lower body weight (63.9 vs 74.4 kg, <em>P</em> = .03). The prevalence of toxicity among PPS users at Emory is estimated as ranging between 3.8% and 24.5%.</div></div><div><h3>Conclusions</h3><div>This comprehensive screening study corroborates that the risk of PPS maculopathy is primarily driven by cumulative PPS exposure but also suggests a possible role for other factors including age, sex, and body weight. These findings have global public safety implications and may help inform dosing guidelines and screening protocols.</div></div>","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"61 4","pages":"Pages 999-1005"},"PeriodicalIF":2.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147653815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic and ophthalmic drugs associated with glaucoma: an international, population-based observational study","authors":"Moiz Lakhani,&nbsp;Nikhil Patil,&nbsp;Emaan Chaudry,&nbsp;Marko M. Popovic,&nbsp;Mathew Palakkamanil,&nbsp;Karim F. Damji","doi":"10.1016/j.jcjo.2026.03.017","DOIUrl":"10.1016/j.jcjo.2026.03.017","url":null,"abstract":"<div><h3>Objective</h3><div>Glaucoma is the leading cause of irreversible blindness worldwide. No postmarketing study has comprehensively assessed Food and Drug Administration (FDA)-approved drugs for glaucoma risk by subtype, therapeutic class, and sex. This study sought to identify systemic and ophthalmic drugs associated with glaucoma-related adverse events (AEs).</div></div><div><h3>Design</h3><div>Population-based pharmacovigilance analysis of FDA Adverse Event Reporting System (FAERS) reports (January 2004–December 2024).</div></div><div><h3>Participants</h3><div>All glaucoma-related AEs, including normal-tension glaucoma (NTG), open-angle glaucoma (OAG), and angle-closure glaucoma (ACG).</div></div><div><h3>Methods</h3><div>Events were identified with the Medical Dictionary for Regulatory Activities Preferred Terms. Disproportionality was assessed using reporting odds ratios (RORs; 95% CI), Evans’ criteria (n &gt; 2; χ² &gt; 4, Proportional reporting ratio &gt; 2) and Bayesian confirmation (information component, lower 95% bound [IC₀₂₅] &gt; 0). Analyses were stratified by subtype and sex.</div></div><div><h3>Results</h3><div>Among 13,237,811 FAERS reports, 2 165 involved glaucoma-related events: 67 NTG, 372 OAG, and 1 726 ACG. Ranibizumab showed the strongest NTG signal (ROR = 83.73; 95% confidence interval [CI] = 38.20–183.66), especially in females (ROR = 162.36; 95% CI = 62.14–424.21). In OAG, significant signals were found for ranibizumab (ROR = 27.13; 95% CI = 15.60–47.19), topiramate (ROR = 21.58; 95% CI = 12.14-38.37), duloxetine (ROR = 9.09; 95% CI = 4.85–17.03), alendronate (ROR = 13.52; 95% CI = 8.78–20.82), and female-specific methylphenidate (ROR = 42.57; 95% CI = 20.94–86.51). In ACG, top signals included tropicamide (ROR = 166.10; 95% CI = 105.18–262.30), topiramate (ROR = 109.19; 95% CI = 98.54–121.00), imipramine (ROR = 33.96; 95% CI = 20.05–57.53), phentermine (ROR = 25.25; 95% CI = 16.73–38.13), and chlorpromazine (ROR = 13.93; 95% CI = 7.69–25.21). Tropicamide, topiramate, and imipramine showed stronger ACG signals in males. All associations were statistically significant (<em>p</em> &lt; 0.0001; IC₀₂₅ &gt; 0).</div></div><div><h3>Conclusions</h3><div>This large-scale FAERS analysis provides the most comprehensive assessment of drug-associated glaucoma risk to date. It confirms known associations and identifies novel signals across anti-vascular endothelial growth factor, cardiovascular, psychiatric, and respiratory drugs. Subtype- and sex-specific patterns underscore the need for individualized risk assessment, targeted postmarketing surveillance, and cautious prescribing to reduce preventable glaucoma-related vision loss.</div></div>","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"61 4","pages":"Pages 866-875"},"PeriodicalIF":2.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147670602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Choroidal abnormalities: the new hallmark ocular finding in neurofibromatosis type 1","authors":"Reda Ghazali,&nbsp;Aurélie Briffault,&nbsp;Marc D. de Smet","doi":"10.1016/j.jcjo.2026.03.021","DOIUrl":"10.1016/j.jcjo.2026.03.021","url":null,"abstract":"","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"61 4","pages":"Pages 1054-1057"},"PeriodicalIF":2.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147688417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uneven geographic distribution of orthoptic services across Canada","authors":"Marie Jo Abdul-Hay,&nbsp;Jocelyn Zurevinsky,&nbsp;Maria Pryde,&nbsp;Stephanie MacLeod,&nbsp;Michael J. Wan","doi":"10.1016/j.jcjo.2026.04.005","DOIUrl":"10.1016/j.jcjo.2026.04.005","url":null,"abstract":"","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"61 4","pages":"Pages 1030-1033"},"PeriodicalIF":2.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Faricimab for recalcitrant neovascular age-related macular degeneration: a real-life study following aflibercept nonresponse","authors":"Carolina Bernal-Morales,&nbsp;Sol Burgos Herrera,&nbsp;Lena Giralt,&nbsp;Socorro Alforja,&nbsp;Barbara Romero-Núñez,&nbsp;Saray Catalan-Coronado,&nbsp;Valentina Bilbao,&nbsp;Anna Sala-Puigdollers,&nbsp;Laura Pelegrin-Colas,&nbsp;Javier Zarranz-Ventura,&nbsp;Alfredo Adan,&nbsp;Ricardo Casaroli-Marano,&nbsp;Marc Figueras-Roca","doi":"10.1016/j.jcjo.2026.02.009","DOIUrl":"10.1016/j.jcjo.2026.02.009","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate anatomical and functional outcomes following a switch to intravitreal faricimab in patients with active, recalcitrant neovascular age-related macular degeneration (nAMD) previously treated with aflibercept in a real-life setting.</div></div><div><h3>Design</h3><div>A retrospective, observational, single-centre study.</div></div><div><h3>Methods</h3><div>Demographic data and prior intravitreal treatment (IVT) history were collected. Best-corrected visual acuity (BCVA) and disease activity were assessed using optical coherence tomography (OCT), including fluid compartments: intraretinal fluid, subretinal fluid (SRF), pigment epithelial detachment, and subretinal hyperreflective material.</div></div><div><h3>Results</h3><div>A total of 161 eyes from 145 patients (mean age: 80.1 ± 7.8 years) were included. Mean prior IVT duration was 2.9 ± 2.5 years. All eyes were active at the time of switching, with 82.0% showing persistent SRF. Disease inactivation occurred in 42.9% of eyes after the switch, more frequently in eyes with shorter prior treatment duration. BCVA remained stable throughout the follow-up. SRF resolved in 50.8% of eyes, with 52.2% achieving resolution after a single injection. Mean treatment intervals increased significantly in inactivated eyes (+4.9 ± 5 weeks). Disease relapse occurred in 54.6% of the initially inactivated eyes. No adverse events were reported.</div></div><div><h3>Conclusions</h3><div>Switching to faricimab may offer a valuable therapeutic option for recalcitrant nAMD, particularly in eyes with persistent SRF, providing improved anatomical outcomes while maintaining visual acuity in real-life practice. Prospective studies are warranted to better define response profiles and guide personalized treatment strategies.</div></div>","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"61 4","pages":"Pages 982-989"},"PeriodicalIF":2.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emergency physician-directed streamlined access to ophthalmology consultations: evaluation of a direct access pathway","authors":"Kristina Nazzicone,&nbsp;Kelly Ann Hutchinson,&nbsp;Aidan Pucchio,&nbsp;Mia Sams,&nbsp;Nirmay Shah,&nbsp;Mark Bona,&nbsp;Stephanie Baxter,&nbsp;Jacob Rullo,&nbsp;Rachel Curtis","doi":"10.1016/j.jcjo.2026.03.005","DOIUrl":"10.1016/j.jcjo.2026.03.005","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the use, safety, and diagnostic accuracy of referrals sent through a direct access pathway for ophthalmic complaints from 2 emergency departments (EDs) to a tertiary emergency ophthalmology clinic.</div></div><div><h3>Design and Participants</h3><div>Cohort study of all referrals from two academic EDs to the Urgent Eye Care Clinic (UECC) at Kingston Health Sciences Centre between July 2, 2024, and March 21, 2025.</div></div><div><h3>Methods</h3><div>Referral data were extracted from electronic medical records, including patient demographics, referral details, and provisional diagnoses. Clinic notes were reviewed to identify the level of training of the primary assessor and the UECC diagnosis. Agreement between provisional and UECC diagnoses was assessed for both diagnostic accuracy and urgency.</div></div><div><h3>Results</h3><div>Two hundred forty-six referrals met the inclusion criteria. The mean ± SD time from referral to assessment was 1.15 ± 0.92 days, with 72% of patients seen within 1 calendar day. Among referrals containing a provisional diagnosis (n = 171), 85% were appropriately triaged as emergent or urgent. Agreement between provisional and final diagnoses occurred in 44% of the cases. ED physicians most accurately identified posterior segment pathology (97.5% agreement), whereas anterior segment disease was frequently misclassified. Overcalling of urgency was common (41%), while undercalling occurred in less than 5% of referrals.</div></div><div><h3>Conclusions</h3><div>Overall, the direct referral pathway presents a safe and effective alternative to the fielding of ED referrals. Most referrals were appropriate, although some were for nonurgent concerns. Strengthening ophthalmic education and encouraging interdisciplinary communication might further optimize referral accuracy.</div></div>","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"61 4","pages":"Pages 894-900"},"PeriodicalIF":2.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147580661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retinal cavernous hemangioma associated with cerebral cavernous malformations in a 6-year-old child","authors":"Abdullah Al-Ani,&nbsp;Zorana Vujadinovic Lynton,&nbsp;Monique Munro","doi":"10.1016/j.jcjo.2026.03.006","DOIUrl":"10.1016/j.jcjo.2026.03.006","url":null,"abstract":"","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"61 4","pages":"Page 1038"},"PeriodicalIF":2.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147580720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}